|
FDA Hands Cornerstone’s Low-Sodium Drug a Complete Response, Wants More Clinical Info
The FDA has shot down Cornerstone Therapeutics’ low-sodium drug lixivaptan for both its proposed indications.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives